Chronic Idiopathic Urticaria: Clinical Trials

6 completed, 1 not yet recruiting, 1 unknown, 1 withdrawn. 9 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	9	Completed 6, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 2	2	Completed 1, Withdrawn 1

Follow Chronic Idiopathic Urticaria: new trials by email Literature Review of Chronic Idiopathic Urticaria trials Research Report on Chronic Idiopathic Urticaria

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. Autologous whole blood therapy, Desloratadine - Chronic Idiopathic Urticaria	Phase 3	Not yet recruiting	Cairo University	40	2026-04-30	2026-03-20
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria Omalizumab Injection, Xolair Prefilled Syringe - Chronic Idiopathic Urticaria	Phase 3	Completed	Kashiv BioSciences, LLC	600	2023-08-15	2025-02-05
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Omalizimab - Chronic Idiopathic Urticaria	Phase 3	Unknown	Rabin Medical Center	20	2014-07-01	2014-06-18
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Omalizumab (Xolair), Placebo - Chronic Urticaria, Chronic Idiopathic Urticaria	Phase 2 / Phase 3	Completed	Insel Gruppe AG, University Hospital Bern	30	2012-09-01	2014-04-15
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Placebo, Omalizumab - Chronic Idiopathic Urticaria	Phase 3	Completed	Genentech, Inc.	323	2011-03-01	2013-10-11
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist - Chronic Idiopathic Urticaria	Phase 3	Completed	Genentech, Inc.	336	2011-02-01	2013-11-26
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Omalizumab, Placebo - Chronic Idiopathic Urticaria	Phase 3	Completed	Genentech, Inc.	319	2011-02-01	2013-11-27
Etanercept for the Treatment of Chronic Urticaria etanercept, placebo - Chronic Idiopathic Urticaria	Phase 2 / Phase 3	Withdrawn	University of Utah		2010-12-01	2015-06-02
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) desloratadine, Placebo - Chronic Idiopathic Urticaria, Atopy	Phase 3	Completed	Organon and Co	97	2002-11-01	2024-08-15

Narrower conditions

Chronic Urticaria (9)  ·  Urticaria (1)

Broader conditions

Chronic Disease (9)  ·  Disease Attributes (9)  ·  Hypersensitivity (9)  ·  Hypersensitivity, Immediate (9)  ·  Immune System Diseases (9)  ·  Pathologic Processes (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Skin Diseases (9)  ·  Skin Diseases, Vascular (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Urticaria (8)

Interventions

Omalizumab (6)  ·  desloratadine (2)  ·  Diphenhydramine (1)  ·  Etanercept (1)  ·  Histamine Antagonists (1)  ·  Leukotriene Antagonists (1)

Sponsors

Genentech, Inc. (3)  ·  Cairo University (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Kashiv BioSciences, LLC (1)  ·  Organon and Co (1)  ·  Rabin Medical Center (1)  ·  University of Utah (1)

Countries

United States (5)  ·  Germany (3)  ·  Poland (3)  ·  Denmark (2)  ·  France (2)  ·  Italy (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Turkey (Türkiye) (2)  ·  Australia (1)  ·  Egypt (1)  ·  India (1)  ·  Israel (1)  ·  Jordan (1)  ·  New Zealand (1)

Top investigators

Christopher Hull, MD (1)  ·  Edward R. Conner, M.D. (1)  ·  Michael David, Prof (1)  ·  Oliver Hausmann (1)

Results publications

PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 39193419, PMID 23432142, PMID 25046337, PMID 41847564